Shanghai Junshi Biosciences Unit Passes US FDA On-Site Inspection; Shares Slide 5%
MT Newswires Live
Oct 23
Shanghai Junshi Biosciences (HKG:1877) said its wholly owned unit, Suzhou Union Biopharm, has passed an unannounced on-site inspection conducted by the US Food and Drug Administration, according to a Wednesday Hong Kong bourse filing.
Shares of the biopharmaceutical firm were down nearly 5% in Thursday morning trade.
The inspection, held from June 16 to June 24, reviewed compliance with current good manufacturing practice standards at Suzhou Union's Wujiang production base, which manufactures the company's toripalimab injection.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.